• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于牛油果脂脂质基质的氢氯噻嗪固体脂质微粒的制备与表征

Formulation and characterization of hydrochlorothiazide solid lipid microparticles based on lipid matrices of Irvingia fat.

作者信息

Agubata Chukwuma O, Chime Salome A, Kenechukwu Franklin C, Nzekwe Ifeanyi T, Onunkwo Godswill C

机构信息

Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka, Enugu, Nigeria.

Department of Pharmaceutics, University of Nigeria, Nsukka, Enugu, Nigeria.

出版信息

Int J Pharm Investig. 2014 Oct;4(4):189-94. doi: 10.4103/2230-973X.143120.

DOI:10.4103/2230-973X.143120
PMID:25426440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4241624/
Abstract

INTRODUCTION

The purpose of this study was to improve the solubilization, bioavailability, and permeability of hydrochlorothiazide (HCTZ) by the formulation and characterization of HCTZ solid lipid microparticles (SLMs) based on fat derived from Irvingia gabonensis var. excelsa (Irvingia wombolu) and Phospholipon(®)90G (P90G).

MATERIALS AND METHODS

Irvingia fat was extracted from the nut of I. gabonensis var. excelsa using petroleum ether (40-60°C). HCTZ loaded SLM were formulated using hot homogenization method with 5% w/w Irvingia fat/P90G at each of 1:0, 9:1, 4:1, and 3:1 ratios, 1% w/w HCTZ, 1.5% w/w Labrasol(®) surfactant and distilled water. Subsequently, particle size analysis, pH, syringeability, drug encapsulation efficiency (EE%), yield, freeze-thaw cycle test, drug release, diffusion, and kinetics were evaluated.

RESULTS

The SLM dispersions showed a particle size range of 10.15 ± 2.36 to 13.50 ± 6.88 μm and pH of 5.6-6.4 while dispersions containing 3:1 Irvingia fat/P90G passed through most of the needles (18G, 21G, and 22G) after syringeability studies. A single freeze-thaw cycle caused loss of physical integrity. The EE% of the SLMs were ≥80%, with high yield. The highest drug release and diffusion was observed with SLMs prepared with 3:1 Irvingia fat-P90G mixture (HDP3) and Higuchi model best described the kinetics of the HCTZ release by Fickian diffusion.

CONCLUSION

The release and permeability of HCTZ was improved by its incorporation into Irvingia fat and P90G (3:1) as SLMs.

摘要

引言

本研究的目的是通过基于加蓬油桃木(Irvingia gabonensis var. excelsa,即Irvingia wombolu)脂肪和磷脂酰胆碱(Phospholipon®90G,简称P90G)制备和表征氢氯噻嗪(HCTZ)固体脂质微粒(SLMs),来提高其溶解性、生物利用度和渗透性。

材料与方法

使用石油醚(40 - 60°C)从加蓬油桃木变种的坚果中提取油桃木脂肪。采用热均质法,以1:0、9:1、4:1和3:1的比例分别使用5% w/w的油桃木脂肪/P90G、1% w/w的HCTZ、1.5% w/w的Labrasol®表面活性剂和蒸馏水来制备负载HCTZ的SLMs。随后,对粒径分析、pH值、可注射性、药物包封率(EE%)、产率、冻融循环试验、药物释放、扩散和动力学进行了评估。

结果

SLMs分散体的粒径范围为10.15 ± 2.36至13.50 ± 6.88μm,pH值为5.6 - 6.4;在可注射性研究后,含有3:1油桃木脂肪/P90G的分散体能够通过大多数针头(18G、21G和22G)。单次冻融循环导致物理完整性丧失。SLMs的EE%≥80%,产率较高。用3:1油桃木脂肪 - P90G混合物(HDP3)制备的SLMs观察到最高的药物释放和扩散,Higuchi模型最能描述HCTZ通过菲克扩散的释放动力学。

结论

将HCTZ制成基于油桃木脂肪和P90G(3:1)的SLMs可提高其释放和渗透性。

相似文献

1
Formulation and characterization of hydrochlorothiazide solid lipid microparticles based on lipid matrices of Irvingia fat.基于牛油果脂脂质基质的氢氯噻嗪固体脂质微粒的制备与表征
Int J Pharm Investig. 2014 Oct;4(4):189-94. doi: 10.4103/2230-973X.143120.
2
Formulation, characterization and anti-malarial activity of homolipid-based artemether microparticles.基于同脂质的蒿甲醚微粒的制剂、表征及抗疟活性
Int J Pharm. 2015 Jan 15;478(1):202-222. doi: 10.1016/j.ijpharm.2014.11.044. Epub 2014 Nov 20.
3
Solid lipid micro-dispersions (SLMs) based on PEGylated solidified reverse micellar solutions (SRMS): a novel carrier system for gentamicin.基于聚乙二醇化固态反胶束溶液(SRMS)的固体脂质微分散体(SLMs):一种新的庆大霉素载体系统。
Drug Deliv. 2015;22(6):710-22. doi: 10.3109/10717544.2014.900152. Epub 2014 Apr 11.
4
Enhanced anti-inflammatory and ulcerogenicity of Ibuprofen microsphere formulations using Irvingia wombolu fat (IRW) and moringa oil (MO) as co-lipids.使用 Irvingia wombolu 脂肪(IRW)和辣木叶油(MO)作为共脂质增强布洛芬微球制剂的抗炎和致溃疡作用。
BMC Complement Med Ther. 2023 Jul 19;23(1):249. doi: 10.1186/s12906-023-04036-2.
5
Pharmacodynamics of piroxicam from novel solid lipid microparticles formulated with homolipids from Bos indicus.新型固体脂质微球中来源于印度野牛同源脂质的吡罗昔康的药效学研究。
Curr Drug Deliv. 2013 Dec;10(6):645-55. doi: 10.2174/156720181006131125145712.
6
Investigation of novel solid lipid microparticles based on homolipids from Bos indicus for the delivery of gentamicin.基于印度瘤牛同源脂质的新型固体脂质微粒用于庆大霉素递送的研究
Int J Pharm Investig. 2016 Jan-Mar;6(1):32-8. doi: 10.4103/2230-973X.176473.
7
PEGylated aceclofenac solid lipid microparticles homolipid-based solidified reverse micellar solutions for drug delivery.聚乙二醇化醋氯芬酸固体脂质微粒:用于药物递送的基于同脂质的固化反胶束溶液
Heliyon. 2022 Apr 6;8(4):e09247. doi: 10.1016/j.heliyon.2022.e09247. eCollection 2022 Apr.
8
Formulation of novel sustained release rifampicin-loaded solid lipid microparticles based on structured lipid matrices from Moringa oleifera.基于辣木籽结构脂质基质的新型载利福平固体脂质微粒缓释制剂的研制。
Pharm Dev Technol. 2015;20(5):546-54. doi: 10.3109/10837450.2014.898654. Epub 2014 Jun 25.
9
Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.含有混合脂质核心和极性异质脂质的固体脂质纳米分散体:表征
Eur J Pharm Biopharm. 2007 Aug;67(1):48-57. doi: 10.1016/j.ejpb.2006.12.004. Epub 2006 Dec 16.
10
Formulation, in vitro and in vivo evaluation of halofantrine-loaded solid lipid microparticles.载卤泛群固体脂质微粒的制剂、体外及体内评价
Pharm Dev Technol. 2015 Dec;20(8):941-948. doi: 10.3109/10837450.2014.949270. Epub 2014 Aug 18.

本文引用的文献

1
Kinetic modeling on drug release from controlled drug delivery systems.药物控释系统中药物释放的动力学建模
Acta Pol Pharm. 2010 May-Jun;67(3):217-23.
2
Low dose lipid formulations: effects on gastric emptying and biliary secretion.低剂量脂质制剂:对胃排空和胆汁分泌的影响。
Pharm Res. 2007 Nov;24(11):2084-96. doi: 10.1007/s11095-007-9363-8. Epub 2007 Jul 27.
3
A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.美国、英国、西班牙和日本排名前200的口服药品的临时生物制药分类。
Mol Pharm. 2006 Nov-Dec;3(6):631-43. doi: 10.1021/mp0600182.
4
Solid lipid microparticles as a sustained release system for pulmonary drug delivery.固体脂质微粒作为肺部药物递送的缓释系统。
Eur J Pharm Biopharm. 2007 Jan;65(1):47-56. doi: 10.1016/j.ejpb.2006.07.006. Epub 2006 Jul 20.
5
Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier.
Eur J Pharm Biopharm. 2005 Sep;61(1-2):77-86. doi: 10.1016/j.ejpb.2005.03.006.
6
MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES.缓释药物的作用机制。分散于固体基质中的固体药物释放速率的理论分析。
J Pharm Sci. 1963 Dec;52:1145-9. doi: 10.1002/jps.2600521210.
7
In-vitro studies of diclofenac sodium controlled-release from biopolymeric hydrophilic matrices.双氯芬酸钠从生物聚合物亲水性基质中的体外控释研究。
J Pharm Pharm Sci. 2002 Sep-Dec;5(3):213-9.
8
Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems.用于药物口服给药的脂质制剂:非乳化、自乳化和“自微乳化”药物递送系统。
Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S93-8. doi: 10.1016/s0928-0987(00)00167-6.
9
What is the true solubility advantage for amorphous pharmaceuticals?无定形药物真正的溶解度优势是什么?
Pharm Res. 2000 Apr;17(4):397-404. doi: 10.1023/a:1007516718048.
10
Effect of bile salts on the gastrointestinal absorption of drugs. I.
Chem Pharm Bull (Tokyo). 1970 Feb;18(2):275-80. doi: 10.1248/cpb.18.275.